Pfizer/Ligand's Lasofoxifene Is First "Next-Generation" SERM Filed At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
NDA for the selective estrogen receptor modulator has an estimated user fee date of June 2005 for post-menopausal osteoporosis prevention indication. Drug could offer benefits over Lilly's SERM Evista, Ligand says.
You may also be interested in...
Advisory Committee Meeting Will Focus On Fablyn’s Mortality Trend
If approved, the osteoporosis drug may struggle to compete with Lilly’s Evista, according to PEARL data.
Advisory Committee Meeting Will Focus On Fablyn’s Mortality Trend
If approved, the osteoporosis drug may struggle to compete with Lilly’s Evista, according to PEARL data.
Pfizer Pipeline Update Includes Resubmission Plans For Osteoporosis Drug Lasofoxifene
The pharma giant has 85 new molecular entities in development, with 99 total programs in Phase I through Phase III.